B
Brendan Gilmore
Researcher at Queen's University Belfast
Publications - 138
Citations - 7378
Brendan Gilmore is an academic researcher from Queen's University Belfast. The author has contributed to research in topics: Biofilm & Antimicrobial. The author has an hindex of 38, co-authored 130 publications receiving 5866 citations.
Papers
More filters
Journal ArticleDOI
Plasmid DNA damage following exposure to atmospheric pressure non-thermal plasma: kinetics and influence of oxygen admixture
Mahmoud Y. Alkawareek,Nida Alshraiedeh,Sarah Higginbotham,Padrig B. Flynn,Qais Th. Algwari,Sean P. Gorman,William Graham,Brendan Gilmore +7 more
TL;DR: In a helium-operated plasma jet, adding oxygen to the feed gas resulted in higher rates of DNA DSB, which increased linearly with increasing oxygen content, up to an optimum level of 0.75% oxygen, after which the DSB rate decreased slightly, indicating an essential role for reactive oxygen species in the rapid degradation of DNA.
Journal ArticleDOI
Strategies for detection and quantification of cysteine cathepsins-evolution from bench to bedside.
TL;DR: This review examines recent innovations in synthetic substrates and protease-labelling with affinity-binding probes (or activity-based probes) as the field moves towards developing tools that could ultimately be used in patients for diagnostic or prognostic applications.
Journal ArticleDOI
Anti‐biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device‐related pathogens
TL;DR: The potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives to demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens is highlighted.
Journal ArticleDOI
Isolation and Characterisation of a Halotolerant ω‐Transaminase from a Triassic Period Salt Mine and Its Application to Biocatalysis
Stephen Kelly,Julianne Megaw,Jill Caswell,Christopher J. Scott,Christopher C. R. Allen,Thomas S. Moody,Brendan Gilmore +6 more
TL;DR: Ad2-TAm exhibits an ability to convert a range of structurally diverse aldehyde and ketone substrates, with no decrease in conversion up to 1.5 M (8.8%) NaCl, making it a promising candidate for industrial applications, whilst also highlighting the value of extreme environments as a source of novel enzymes for the pharmaceutical industry as a whole.
Journal ArticleDOI
Characterisation of a solvent-tolerant haloarchaeal (R)-selective transaminase isolated from a Triassic period salt mine.
Stephen Kelly,Damian J. Magill,Julianne Megaw,Timofey Skvortsov,Thorsten Allers,John W. McGrath,Christopher C. R. Allen,Thomas S. Moody,Brendan Gilmore +8 more
TL;DR: The isolation of the first haloarchaeal TAm (BC61-TAm) to be characterised for the purposes of pharmaceutical biocatalysis is reported, representing an exciting advance in the study of transaminases from extremophiles, providing a possible scaffold for future discovery ofBiocatalytic enzymes with robust properties.